A First-In-Human Phase 1/2 Open-label, Multicentre, Dose Escalation and Expansion Trial of VERT-002 in Locally Advanced or Metastatic Solid Tumors including NSCLC with MET Alterations
September 11, 2026
A Phase 1/2 Trial of Quaratusugene Ozeplasmid and Atezolizumab Maintenance Therapy in Extensive Stage Small Cell Lung Cancer (ES-SCLC)